Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 6.32% is in line with its 5-year average of 5.81%, near the high end of its 5-year range (-1.58%–7.25%).
3.53% below its 12-month average of 6.55%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 6.81%.
EBITDA MARGIN
6.32%
EBITDA MARGIN AVG TTM
6.55%
EBITDA MARGIN AVG 3Y
6.37%
EBITDA MARGIN AVG 5Y
5.81%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-3.53%
CURRENT VS 3Y AVG
-0.86%
CURRENT VS 5Y AVG
+8.76%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
The Pennant Group, Inc.
Market Cap
$1.39B
EBITDA Margin
6.32%
TTM Avg
6.55%
3Y Avg
6.37%
5Y Avg
5.81%
Market Cap
$1.40B
EBITDA Margin
-1118.93%
TTM Avg
-1100.77%
3Y Avg
-1899.79%
5Y Avg
-1899.79%
Market Cap
$1.37B
EBITDA Margin
-10195.54%
TTM Avg
-87388.52%
3Y Avg
-48181.08%
5Y Avg
-32386.50%
Market Cap
$1.41B
EBITDA Margin
21.45%
TTM Avg
-50.92%
3Y Avg
-538.26%
5Y Avg
-378.46%
Market Cap
$1.43B
EBITDA Margin
-74.29%
TTM Avg
-81.81%
3Y Avg
-115.58%
5Y Avg
-114.07%
Market Cap
$1.44B
EBITDA Margin
3.56%
TTM Avg
3.76%
3Y Avg
3.79%
5Y Avg
3.46%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| The Pennant Group, Inc. (PNTG) | $1.39B | 6.32% | 6.55% | 6.37% | 5.81% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | -1118.93% | -1100.77% | -1899.79% | -1899.79% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | -10195.54% | -87388.52% | -48181.08% | -32386.50% |
| AnaptysBio, Inc. (ANAB)vs › | $1.41B | 21.45% | -50.92% | -538.26% | -378.46% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.43B | -74.29% | -81.81% | -115.58% | -114.07% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.44B | 3.56% | 3.76% | 3.79% | 3.46% |
| Certara, Inc. (CERT)vs › | $1.45B | 18.52% | 17.87% | 16.34% | 15.57% |
| Omeros Corporation (OMER)vs › | $1.34B | -55.09% | -213.80% | -156.04% | -2346.33% |
Gross Margin
14.8%
EBITDA Margin
6.3%
Operating Margin
5.8%
Net Margin
2.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 6.81% |
| 2026-03-31 | 7.25% |
| 2025-12-31 | 7.06% |
| 2025-09-30 | 5.37% |
| 2025-06-30 | 6.27% |
| 2025-03-31 | 6.93% |
| 2024-12-31 | 5.86% |
| 2024-09-30 | 6.80% |
| 2024-06-30 | 6.54% |
| 2024-03-31 | 6.28% |
| 2023-12-31 | 6.08% |
| 2023-09-30 | 5.98% |
| 2023-06-30 | 5.65% |
| 2023-03-31 | 4.40% |
| 2022-12-31 | 6.10% |
| 2022-09-30 | 7.09% |
| 2022-06-30 | -1.58% |
| 2022-03-31 | 3.05% |
| 2021-12-31 | -0.85% |
| 2021-09-30 | 2.59% |
| 2021-06-30 | 4.29% |
| 2021-03-31 | 2.64% |
| 2020-12-31 | 4.94% |
| 2020-09-30 | 5.78% |
| 2020-06-30 | 7.85% |
| 2020-03-31 | 5.76% |
| 2019-12-31 | -0.48% |
| 2019-09-30 | 3.39% |
| 2019-06-30 | 5.17% |
| 2019-03-31 | 3.38% |
| 2018-12-31 | 7.30% |
| 2018-09-30 | 8.97% |
| 2018-06-30 | 8.99% |
| 2018-03-31 | 7.76% |
